Mode of Progression After Frontline Treatment Predicts Clinical Outcomes in Patients With CLL
Inferior survival for patients with chronic lymphocytic leukemia who progress with lymphadenopathy
All articles by Megan Garlapow, PhD
Improved Clinical Outcomes in Relapsed/Refractory Multiple Myeloma With Daratumumab Re-Treatment
Patients who were naive to daratumumab experienced an overall response rate of 91.7%; median progression-free survival in this cohort was not reached.
Prognostic Factors After Second Allogeneic HSCT in Patients With Relapsed Myelodysplastic Syndrome
The rate of 5-year overall survival in patients with myelodysplastic syndrome who underwent second allogeneic hematopoietic stem cell transplantation was 25.3%.
Pharmacokinetic-Guided Hydroxyurea Dosing Beneficial for Very Young Children With Sickle Cell Disease
Young patients with sickle cell disease underwent dosing schedules guided by analysis of pharmacokinetic data using a population pharmacokinetic model.
Factors Associated With Long-Term Fatigue in Non-Hodgkin Lymphoma Survivors
Severe fatigue was more common in NHL survivors compared with the general population.
Response to Iron Chelation Therapy May Predict Improvement in Transfusion-Dependent Myelofibrosis
Patients who experienced an iron chelation response had lower transfusion burden and substantial decrease in ferritin values.
Greater Infection Risk With Unrelated Transplant Donors in Pediatric Acute Lymphoblastic Leukemia
The increased risk for infection seen in pediatric patients receiving transplants from unrelated donors could be a result of intensified graft-versus-host disease prophylaxis.
Relapse Predictors in Immune Thrombotic Thrombocytopenic Purpura After Rituximab Treatment
Rituximab treatment conferred short-term benefit against subsequent relapse, though this benefit decreased over time.
Safety of Allogeneic HSCT for Patients With Hepatitis-Associated Aplastic Anemia
Patients demonstrated a 5-year overall survival rate of 86%, with all but 2 patients achieving neutrophil engraftment.
Ibrutinib Added to R-CHOP May Improve Outcomes for Patients Younger Than 60 Years
Though the primary survival endpoints were not met in this study, younger patients experienced improved outcomes with ibrutinib.
Next post in Lymphoma
